ArticleActa biomaterialia2025
Exploration of biomaterial-tissue integration in heterogeneous microporous annealed particle scaffolds in subcutaneous implants over 12 months.
Article in Acta biomaterialia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microporous annealed particle scaffolds avoid foreign body response by down regulating complement-fibroblast-macrophage signaling loop.bioRxiv : the preprint server for biology · 2026Article
- Granular Hydrogels as Modular Biomaterials: From Structural Design to Biological Responses.Advanced healthcare materials · 2026Review
- From "immune silence" to "immune dialogue": modification strategies for bone substitutes based on bone immunomodulatory characteristics.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Microporous annealed particle (MAP) scaffolds are comprised of hydrogel microparticles with inter- and intra-particle cross-links that provide structure and cell-scale porosity, making them an increasingly attractive option for injectable tissue augmentation. Many current injectable biomaterials create a substantial foreign body response (FBR), while MAP scaffolds mitigate this response and have the potential to facilitate the formation of new tissue, though this de novo tissue formation is poorly understood. Here, we leverage a subcutaneous implant model to explore the maturation of MAP implants with and without heparin microislands (µislands) over one year to identify the effect of bioactive particles on scaffold maturation. Implants were measured and explanted after 1, 3, 6, and 12 months and analyzed using immunofluorescence staining and RNA-sequencing. No fibrous capsule or significant FBR was observed, and though a significant amount of MAP remains at 12 months, we still see a volume decrease over time. Heparin µislands facilitate increased cell infiltration and recruit a wider variety of cells at 1 month than blank MAP scaffolds, although this effect diminishes after 3 months. Transcriptomics reveal a potential activation of the complement-mediated immune response at 12 months in both groups, possibly associated with pore collapse in the implants. A single 12-month sample avoided this outcome, yielding complete cell infiltration, vascularization, and substantial matrix deposition throughout. Future work will characterize the effect of implantation site and facilitate increased matrix deposition to support the scaffold and prevent pore collapse. STATEMENT OF SIGNIFICANCE: Injectable biomaterials are increasingly used clinically for soft tissue augmentation and regeneration but still face significant issues from the foreign body reaction. While some materials intentionally promote this response to stimulate collagen deposition, porous materials like MAP scaffolds can mitigate the immune response and allow for true tissue integration. However, this integration is poorly understood, particularly on long timescales, as traditional materials are dominated by inflammatory signals. In this work, we leverage a minimally inflammatory subcutaneous implant to investigate the maturation of MAP scaffolds with and without bioactive heparin-containing particles. The results presented here contribute a better understanding of the long-term material-tissue dynamics of MAP scaffolds that can inform future material design for tissue augmentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.